Seamus Fernandez
Stock Analyst at Guggenheim
(4.04)
# 808
Out of 4,479 analysts
47
Total ratings
53.19%
Success rate
11.25%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALT Altimmune | Downgrades: Neutral | n/a | $6.74 | - | 3 | Apr 29, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $44 → $91 | $38.21 | +138.16% | 3 | Mar 5, 2024 | |
| GSK GSK | Upgrades: Buy | n/a | $38.21 | - | 1 | Mar 4, 2024 | |
| HLVX HilleVax | Maintains: Buy | $38 → $34 | $14.28 | +138.10% | 2 | Nov 15, 2023 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $55 | $5.00 | +1,000.00% | 1 | Aug 15, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | n/a | $21.48 | - | 2 | Jul 14, 2023 | |
| MRK Merck & Co. | Maintains: Buy | $123 → $124 | $127.72 | -2.91% | 7 | Apr 11, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $395 → $392 | $906.71 | -56.77% | 4 | Apr 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $32 | $12.09 | +164.68% | 1 | Mar 7, 2023 | |
| PCVX Vaxcyte | Maintains: Buy | $66 → $65 | $76.06 | -14.54% | 2 | Feb 28, 2023 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $38.73 | +29.10% | 1 | Feb 28, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | n/a | $40.45 | - | 5 | Oct 10, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $142.98 | - | 2 | May 31, 2022 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $106.44 | - | 3 | Feb 25, 2020 | |
| DERM Journey Medical | Downgrades: Neutral | n/a | $5.24 | - | 1 | Feb 3, 2020 | |
| ITCI Intra-Cellular Therapies | Initiates: Outperform | n/a | $68.54 | - | 3 | Nov 15, 2018 | |
| ACRS Aclaris Therapeutics | Maintains: Outperform | n/a | $1.14 | - | 1 | Mar 13, 2018 | |
| CLDX Celldex Therapeutics | Maintains: Market Perform | n/a | $37.01 | - | 1 | Mar 8, 2018 | |
| AZN AstraZeneca | Maintains: Market Perform | n/a | $76.99 | - | 3 | Feb 6, 2018 | |
| PFE Pfizer | Maintains: Market Perform | n/a | $27.83 | - | 1 | Jan 31, 2018 |
Altimmune
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.74
Upside: -
Apogee Therapeutics
Mar 5, 2024
Maintains: Buy
Price Target: $44 → $91
Current: $38.21
Upside: +138.16%
GSK
Mar 4, 2024
Upgrades: Buy
Price Target: n/a
Current: $38.21
Upside: -
HilleVax
Nov 15, 2023
Maintains: Buy
Price Target: $38 → $34
Current: $14.28
Upside: +138.10%
Verve Therapeutics
Aug 15, 2023
Maintains: Buy
Price Target: $56 → $55
Current: $5.00
Upside: +1,000.00%
Arcturus Therapeutics Holdings
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $21.48
Upside: -
Merck & Co.
Apr 11, 2023
Maintains: Buy
Price Target: $123 → $124
Current: $127.72
Upside: -2.91%
Eli Lilly
Apr 11, 2023
Maintains: Buy
Price Target: $395 → $392
Current: $906.71
Upside: -56.77%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Buy
Price Target: $32
Current: $12.09
Upside: +164.68%
Vaxcyte
Feb 28, 2023
Maintains: Buy
Price Target: $66 → $65
Current: $76.06
Upside: -14.54%
Structure Therapeutics
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $38.73
Upside: +29.10%
Bristol-Myers Squibb Company
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $40.45
Upside: -
Novo Nordisk
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $142.98
Upside: -
Novartis AG
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $106.44
Upside: -
Journey Medical
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.24
Upside: -
Intra-Cellular Therapies
Nov 15, 2018
Initiates: Outperform
Price Target: n/a
Current: $68.54
Upside: -
Aclaris Therapeutics
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $1.14
Upside: -
Celldex Therapeutics
Mar 8, 2018
Maintains: Market Perform
Price Target: n/a
Current: $37.01
Upside: -
AstraZeneca
Feb 6, 2018
Maintains: Market Perform
Price Target: n/a
Current: $76.99
Upside: -
Pfizer
Jan 31, 2018
Maintains: Market Perform
Price Target: n/a
Current: $27.83
Upside: -